A Study Evaluating the Efficacy and Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combination With Ondansetron and Dexamethasone in Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation

Trial Profile

A Study Evaluating the Efficacy and Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combination With Ondansetron and Dexamethasone in Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation

Completed
Phase of Trial: Phase 0

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Aprepitant (Primary) ; Dexamethasone; Ondansetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2013 Actual end date changed from 1 Feb 2010 to 1 Dec 2008 as reported by ClinicalTrials.gov.
    • 01 Mar 2013 Actual end date changed from 1 Feb 2010 to 1 Dec 2008 as reported by ClinicalTrials.gov.
    • 01 Mar 2013 Actual initiation date changed from 1 Mar 2006 to to 1 Oct 2005 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top